Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRL | P40313 | 11/20 | 0.72 |
| ▸ | TMPRSS11D | O60235 | 5/20 | 0.72 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.51 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.51 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.51 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.51 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.51 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.51 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.51 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.51 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.51 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131859 | 0.95 | CTRL (0.77) | CTRLTMPRSS11DMMEPSMB5PSMB9 | |
| SCHEMBL19341792 | 0.93 | CTRL (0.83) | CTRLTMPRSS11DPSMB5PSMB9PSMB11 | |
| SCHEMBL8141353 | 0.93 | CTRL (0.83) | CTRLTMPRSS11DPSMB5PSMB9PSMB11 | |
| SCHEMBL19289772 | 0.93 | CTRL (0.83) | CTRLTMPRSS11DPSMB5PSMB9PSMB11 | |
| SCHEMBL8132667 | 0.93 | CTRL (0.83) | CTRLTMPRSS11DPSMB5PSMB9PSMB11 | |
| SCHEMBL8132138 | 0.93 | CTRL (0.74) | CTRLTMPRSS11DMMEPSMB5PSMB9 | |
| SCHEMBL8130815 | 0.92 | CTRL (0.79) | CTRLTMPRSS11DMMEPSMB5PSMB9 | |
| SCHEMBL8129093 | 0.91 | CTRL (0.75) | CTRLTMPRSS11DMMEPSMB5PSMB9 | |
| SCHEMBL8122776 | 0.91 | CTRL (0.71) | CTRLTMPRSS11DMMEPSMB5PSMB9 | |
| SCHEMBL8132192 | 0.91 | CTRL (0.71) | CTRLTMPRSS11DMMEPSMB5PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | CTRL 25/4885TMPRSS11D 270/4885MME 43/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | CTRL 27/4885TMPRSS11D 311/4885MME 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.